HK Stock Market Move | JUNSHI BIO(01877) rises by more than 5%, expected to narrow the annual net loss attributable to the parent company by about 31.85% year-on-year in 2025.

JUNSHI BIO (01877) rose more than 5%, as of the time of publication, it rose by 4.81% to 21.8 Hong Kong dollars, with a turnover of 399.148 million Hong Kong dollars. On the news front, recently, JUNSHI BIO announced that it is expected to achieve an operating income of around 2.5 billion yuan in 2025, an increase of about 28.32% year-on-year. It is expected that the research and development expenses for the year 2025 will be 1.353 billion yuan, an increase of about 6.10% year-on-year. It is expected that the net loss attributable to the owners of the parent company in 2025 will be around 873 million yuan, a decrease of about 31.85% year-on-year. It is expected that the net loss attributable to the owners of the parent company after deducting the impact of share-based payments in 2025 will be around 799 million yuan, a decrease of about 37.62% year-on-year. It is expected that the net loss attributable to the owners of the parent company after deducting non-recurring gains and losses in 2025 will be around 985 million yuan, a decrease of about 23.64% year-on-year. The announcement stated that the net profit attributable to the owners of the parent company in 2025 will still be in a loss, but the amount of the loss is significantly narrowed compared to the same period last year, mainly due to the company's continued implementation of the "improving quality and efficiency for returning rewards" action plan, significant enhancement of commercialization capabilities, while continuously strengthening cost control and resource focus. During the reporting period, the company's operating income increased, mainly due to the increase in sales revenue of commercialized drugs compared to the same period last year. During the reporting period, the company's core product, Teriprisin monoclonal antibody injection (trade name: Tuo Yi), saw a significant year-on-year growth in sales revenue in the domestic market. As of the date of this announcement, Tuo Yi has been included in the national medical insurance catalogue for all 12 indications for which it has been approved for listing in mainland China, and is the only anti-PD-1 monoclonal antibody drug used for the treatment of kidney cancer, triple-negative breast cancer, and melanoma in the catalogue.